Aptevo Therapeutics Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
APVO Nasdaq 2836 www.aptevotherapeutics.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Aptevo Therapeutics Inc.

Aptevo's Peter Pavlik, PhD, Chairing Session on "Bi and Multispecific Biologics" at Cambridge Healthcare Institute's Pep Talk 2025 - Jan 15th, 2025 1:00 pm
Aptevo Therapeutics Announces Exercise of Warrants for $6.2 Million Gross Proceeds - Dec 12th, 2024 5:50 pm
100% of Patients Achieve Remission Within 30 Days in Cohort 1 of Bispecific Mipletamig Frontline AML Trial - Dec 12th, 2024 2:00 pm
Bispecific Antibody, APVO442, Differentiated to Treat Prostate Cancer with Precision Tumor Targeting and Reduced Risk of Side Effects - Dec 4th, 2024 1:35 pm
Aptevo Therapeutics Announces 1-for 37 Reverse Stock Split As Part of Nasdaq Compliance Plan - Nov 29th, 2024 2:55 pm
Proving the Concept: Aptevo Technology, Pipeline, to Exemplify the Speed and Power of Modular Biotherapeutics at Presentation - Nov 26th, 2024 1:35 pm
Aptevo Highlights the Potential of the Company's Robust Portfolio in Cancer Immunotherapy, the Success of Bispecifics as a Category, and Their Growing Importance in the Oncology Treatment Paradigm - Nov 22nd, 2024 1:35 pm
First Patient Dosed in Aptevo's Ongoing RAINIER Trial Achieves 90% Reduction in Leukemic Blasts Within the First 30 Days of Treatment, Continues Overall Efficacy Trend Seen in Prior Mipletamig AML Studies - Nov 20th, 2024 1:35 pm
First-in-Class Bispecific Antibody, ALG.APV-527, Meets Important Trial Endpoints in Phase 1 Solid Tumor Trial - Nov 11th, 2024 1:05 pm
Aptevo Therapeutics Reports 3Q 2024 Financial Results and Provides a Business Update - Nov 7th, 2024 1:05 pm
Aptevo Therapeutics and Alligator Bioscience to Present Additional Positive Interim Phase 1 Data Evaluating ALG.APV-527 Monotherapy in Multiple Solid Tumor Types, at SITC 2024 - Oct 29th, 2024 12:05 pm
Aptevo Therapeutics Announces Closing of $3.0 Million Offering Priced At-the-Market Under Nasdaq Rules - Sep 18th, 2024 8:05 pm
Aptevo Therapeutics Announces $3.0 Million Offering Priced At-the-Market Under Nasdaq Rules - Sep 17th, 2024 12:05 am
Aptevo Therapeutics and Alligator Bioscience Announce Data from Phase 1 ALG.APV-527 Monotherapy Trial Showing 60% of Evaluable Patients Achieved Stable Disease in Solid Tumor Study - Sep 16th, 2024 12:05 pm
Aptevo Therapeutics and Alligator Bioscience to Present Positive Interim Phase 1 Data Evaluating ALG.APV-527 Monotherapy in Multiple Solid Tumor Types, at ESMO Congress 2024 - Sep 13th, 2024 12:05 pm
Phase 1b/2 "RAINIER" Frontline Acute Myeloid Leukemia (AML) Trial Initiated - Aug 13th, 2024 12:05 pm
Aptevo Therapeutics Reports 2Q 2024 Financial Results and Provides a Business Update - Aug 8th, 2024 12:05 pm
Aptevo Therapeutics Announces Closing of $2.75 Million Offering - Jul 1st, 2024 8:20 pm
Aptevo Therapeutics Announces $2.75 Million Offering Priced At-the-Market Under Nasdaq Rules - Jun 28th, 2024 1:20 pm
Aptevo Participating in the BIO International Convention - Jun 3rd, 2024 12:05 pm